Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.3052W HIGH $1,210.00
Volume
281.62 K
Value Traded
510.01 K
Short % Float
11.84%
-15.27%Week
-29.61%1 Month
-70.88%3 Month
-91.85%6 Month
-99.99%5 Year
-99.99%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.91 M
EPS (TTM)
-20.13
P/E Ratio
-
Ent. Value
-13.24 M
Total Shares
819.71 K
Float Shares
820.00 K
Insiders
0.21%
Institutions
1.66%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
GNPX Catalyst Timeline
Dated clinical, regulatory and corporate events for Genprex, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Genprex, Inc.
263Total events
4Upcoming
32Tier-1 (high impact)
2016 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Manufacturing MilestoneCMC / Inspection
Genprex selects Andelyn Biosciences for scale-up manufacturing of diabetes gene therapy candidate
Type 1 and Type 2 diabetessource ↗
▲Manufacturing MilestoneCMC / Inspection
Entered into development and manufacturing agreement with CDMO for manufacturing scale-up of diabetes gene therapy program
Type 1 diabetes and Type 2 diabetessource ↗
▲Partnership / LicenseCorporate
Collaboration with Roche Diagnostics for biomarker assay validation
non-small cell lung cancersource ↗
▲Patent GrantedReqorsaIP / Competition
Notice of Allowance from Canadian Intellectual Property Office for patent covering Reqorsa in combination with PD-1 or PD-L1 antibodies
non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)source ↗
◆AbstractPresentation
Abstract selected for publication at 2026 ASCO Annual Meeting on predictive biomarkers in patients receiving Reqorsa
lung cancersource ↗
▲Poster PresentationReqorsaPresentation
Abstract published at 2026 ASCO Annual Meeting on predictive biomarkers for PFS in patients receiving quaratusugene ozeplasmid
Non-Small Cell Lung Cancersource ↗
▲Biomarker DataReqorsaClinical Data
Additional analysis completed: high (3+) Trop-2 expression shows strong relationship with PFS (p=0.053)
Non-Small Cell Lung Cancersource ↗
◆Poster PresentationGPX-002Presentation
Poster presentation of preclinical data for GPX-002 at ASGCT 2026
Type 2 diabetessource ↗
▲Patent GrantedReqorsaIP / Competition
Patent granted by Israel Patent Office for Reqorsa in combination with PD-1 antibodies
cancersource ↗
▲Partnership / LicenseReqorsaCorporate
Genprex signs Sponsored Research Agreement with MD Anderson to study TROP2 and PTEN biomarkers for Reqorsa
non-small cell lung cancer, small cell lung cancersource ↗
◆Enrollment UpdateReqorsaTrial
Genprex is currently enrolling and treating patients in Phase 2a expansion of Acclaim-1
non-small cell lung cancersource ↗
▲Primary Endpoint MetReqorsaClinical Data
Phase 1 dose escalation portion of Acclaim-1 completed with no DLTs and early signs of efficacy
non-small cell lung cancersource ↗
▲Poster PresentationReqorsaPresentation
Poster presentation on Quaratusugene ozeplasmid mediated TUSC2 upregulation in EML4-ALK bearing NSCLC at AACR 2026
ALK-positive non-small cell lung cancersource ↗
◆Poster PresentationPresentation
Poster presentation on TROP2 and PTEN as biomarkers of resistance to TUSC2 gene therapy in NSCLC at AACR 2026
non-small cell lung cancersource ↗
▲Patent GrantedReqorsaIP / Competition
Japanese Patent Office issued favorable Appeal Decision to grant patent for REQORSA in combination with PD-L1 antibodies
cancersource ↗
▲Enrollment UpdateReqorsaTrial
New clinical trial site opened at University of Kentucky for Acclaim-3
extensive stage small cell lung cancer (ES-SCLC)source ↗
▲Patent GrantedReqorsaIP / Competition
IP Australia issued Notice of Acceptance for patent covering REQORSA in combination with PD-L1 antibodies
cancerssource ↗
▲Preclinical PoCGPX-002Preclinical
Positive preliminary preclinical data from GPX-002 in T2D non-human primate and mouse studies
Type 2 diabetessource ↗
◆Enrollment MilestoneReqorsaTrial
Expects to complete enrollment of first 25 patients for interim analysis in Phase 2 expansion portion
extensive stage small cell lung cancersource ↗
◆Interim AnalysisReqorsaTrial
Plans interim analysis after 25th patient reaches 18 weeks follow-up in Acclaim-3
extensive stage small cell lung cancer (ES-SCLC)source ↗
▲PublicationReqorsaPresentation
Publication of Acclaim-1 Phase 1 data in Clinical Lung Cancer
non-small cell lung cancersource ↗
▲Enrollment UpdateReqorsaTrial
Added Gabrail Cancer Center as new clinical trial site for Acclaim-3
extensive stage small cell lung cancer (ES-SCLC)source ↗
▲Patent GrantedReqorsaIP / Competition
USPTO grants patent covering Reqorsa in combination with PD-L1 antibodies through 2037
cancersource ↗
▲Patent GrantedReqorsaIP / Competition
European Patent Office intends to grant patent for REQORSA in combination with PD-1 antibodies
cancersource ↗
▼Equity OfferingCorporate
Registered direct offering of up to $10.0 million priced at-the-market
▲Poster PresentationReqorsaPresentation
Poster presentation of preclinical data for Reqorsa in ALK+ NSCLC at AACR-NCI-EORTC 2025
ALK-EML4 positive non-small cell lung cancersource ↗
◆Poster PresentationPresentation
Poster presentation of preclinical data on Reqorsa Gene Therapy for ALK+ NSCLC at 2025 AACR-NCI-EORTC Conference
ALK-EML4 positive non-small cell lung cancersource ↗
▼Equity OfferingCorporate
Registered direct offering of up to $8.1 million priced at-the-market
◆Oral PresentationPresentation
H.C. Wainwright 27th Annual Global Investment Conference presentation (on-demand)
▲Patent GrantedReqorsaIP / Competition
European Patent Office issues Notice of Allowance for patent covering Reqorsa in combination with PD-1 antibodies
cancersource ↗
▲Oral PresentationGPX-002Presentation
Oral presentation at ADA 85th Scientific Sessions on GPX-002 preclinical data in NHP model
Type 1 Diabetessource ↗
▲Preclinical PoCGPX-002Preclinical
Preclinical proof-of-concept data in NHP model of T1D presented
Type 1 Diabetessource ↗
◆Poster PresentationGPX-002Presentation
Poster presentation on selecting lipid nanoparticles for transfection of islets of Langerhans cells at ADA 85th Scientific Sessions
Type 1 Diabetes, Type 2 Diabetessource ↗
◆Poster PresentationReqorsaPresentation
Poster presentation of Acclaim-3 trial design at 2025 ASCO Annual Meeting
extensive stage small cell lung cancer (ES-SCLC)source ↗
▲Oral PresentationGPX-002Presentation
Oral presentation of preclinical data on GPX-002 at ASGCT 28th Annual Meeting
Diabetes (Type 1 and Type 2)source ↗
▲Preclinical PoCGPX-002Preclinical
Preclinical data presented showing GPX-002 improves glucose tolerance in NHP model
Diabetes (Type 1 and Type 2)source ↗
▲Preclinical PoCGPX-002Preclinical
Preclinical data showed statistically significant decreases in insulin requirements, increases in c-peptide levels and improvements in glucose tolerance in T1D animal model
Type 1 diabetessource ↗
▲Partnership / LicenseGPX-002Corporate
New Sponsored Research Agreement with University of Pittsburgh to study GPX-002 in T1D and T2D animal models
Type 1 diabetes, Type 2 diabetessource ↗
▲Partnership / LicenseCorporate
Exclusive patent license agreement with UTHealth Houston for REQORSA in glioblastoma
glioblastomasource ↗
▲Poster PresentationReqorsaPresentation
Poster presentation of preclinical data for Reqorsa alone and in combination with sotorasib in Ras inhibitor resistant NSCLC at AACR 2025
KRASG12C mutant non-small cell lung cancer (NSCLC)source ↗
◆Poster PresentationPresentation
Poster presentation at AACR 2025 on overcoming sotorasib acquired resistance in KRASG12C mutant NSCLC by TUSC2 gene therapy
KRASG12C mutant non-small cell lung cancersource ↗
▲Partnership / LicenseCorporate
Exclusive patent license agreement with NYU Langone Health for Reqorsa in mesothelioma
mesotheliomasource ↗
▲Preclinical PoCPreclinical
Positive preclinical data published in Cancer Research supplement showing REQORSA overcomes sotorasib acquired resistance in KRASG12C mutant NSCLC models
KRASG12C mutant non-small cell lung cancersource ↗
◆FDA Feedback ReceivedGPX-002FDA Meeting
FDA guidance on IND-enabling diabetes studies expected in second half of 2025
Type 1 and Type 2 diabetessource ↗
◆Enrollment MilestoneReqorsaTrial
Expects to complete enrollment of first 25 patients in Phase 2 expansion for interim analysis
extensive stage small cell lung cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How GNPX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-13 | Pdx1/MafA gene therapy (PM / GPX-002) | Pre-clinical data readout | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 82%
Micro Cap(rank 538 of 656)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| quaratusugene ozeplasmid Gene therapyNCT04486833 | Carcinoma, Non-Small Cell Lung | Phase 1 | RECRUITING | 158 | Mar 1, 2029 | ||||||
| quaratusugene ozeplasmid Gene therapyNCT05703971 | Small Cell Lung Cancer Extensive Stage | Phase 1 | RECRUITING | 62 | Jun 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every GNPX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Reqorsa® Gene Therapy Fast TrackOrphan | non-small cell lung cancer | 2026-05-26 | Trop-2 H-scores above 100 correlated with prolonged PFS (p=0.05); PTEN H-scores below 100 correlated with prolonged PFS (p=0.03)Read More | Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| LONGNECKER BRENT MDirector | Sell | -10 | $1.23 | 04/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in GNPX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in GNPX for Q2 2026. | ||||
GNPX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How GNPX ranks across every disease it competes in
Competitive Position is a premium feature
See how GNPX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialGNPX News
GNPXGenprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Genprex, Inc. will present at the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16 in New York City. The presentation will focus on the company's lead clinical oncology candidate, Reqorsa® Gene Therapy, and its preclinical diabetes program. Key executives will discuss development priorities and engage in one-on-one meetings with investors.
Read more →GNPXAndelyn Biosciences to Scale Manufacturing for Genprex's Diabetes Gene Therapy Program
Genprex, Inc. has partnered with Andelyn Biosciences to scale up manufacturing for its diabetes gene therapy program. This collaboration focuses on optimizing the AAV-based therapy designed to treat both Type 1 and Type 2 diabetes. Preclinical studies have shown encouraging results, including the restoration of normal blood glucose levels in Type 1 diabetes models. The transition to cGMP manufacturing is a critical step toward clinical trials.
Read more →GNPX▼ -11.7%on this news
Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy
Genprex, Inc. has partnered with a leading CDMO to scale up manufacturing of its diabetes gene therapy. This collaboration will transition the therapy from research-grade production to clinical-ready output, facilitating IND-enabling preclinical studies and future clinical trials. The company aims to enhance the safety and efficacy of its therapy for Type 1 and Type 2 diabetes.
Read more →GNPX▼ -20.7%on this news
Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies
Genprex, Inc. has announced a collaboration with Roche Diagnostics to validate biomarkers for patient selection in clinical trials targeting non-small cell lung cancer (NSCLC). This partnership aims to refine patient identification using TROP2 as a biomarker, leveraging Roche's expertise and previously established methods. The validation studies are expected to be completed by the end of 2026, potentially enhancing treatment options for NSCLC patients.
Read more →GNPX▼ -7.1%on this news· ran to -20% by day 3
Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer
Genprex, Inc. has received a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering the combination of Reqorsa® Gene Therapy with PD-1 or PD-L1 antibodies for treating non-small cell and small cell lung cancer. This patent enhances Genprex's intellectual property portfolio and supports their Acclaim-3 clinical trial. The trial evaluates Reqorsa in combination with Genentech's Tecentriq® as maintenance therapy for extensive stage small cell lung cancer.
Read more →GNPX▲ +10.9%on this news· ran to +36% by day 1shared move
Genprex to Participate at BIO International Convention 2026
Genprex, Inc. will participate in the BIO International Convention 2026 in San Diego, showcasing its gene therapies for cancer and diabetes. Thomas Gallagher, Senior VP of Intellectual Property and Licensing, will be available for meetings with industry groups. The convention is expected to attract over 20,000 biotech leaders, providing Genprex an opportunity to enhance its visibility in the sector.
Read more →GNPX▼ -6%on this news
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting
Genprex, Inc. announced the publication of positive clinical findings about its Reqorsa® Gene Therapy at the 2026 ASCO Annual Meeting. The research highlights correlations between Trop-2 and PTEN biomarkers and progression-free survival in patients with non-small cell lung cancer (NSCLC). Levels of Trop-2 above 100 and PTEN below 100 were linked to longer survival rates, enhancing the potential for personalized treatment approaches. The findings build on earlier preclinical studies and signify progress in the gene therapy landscape for lung cancer.
Read more →GNPXGenprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
Genprex, Inc. announced positive preclinical data for its diabetes gene therapy at the 2026 ASGCT Annual Meeting. The Pdx1/MafA gene therapy demonstrated the ability to reverse hyperglycemia in Type 2 diabetic mouse models within four weeks. This therapy aims to address beta-cell dysfunction and could provide long-term glycemic control for diabetic patients.
Read more →GNPX▲ +12.1%on this news
Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
Genprex, Inc. has received a patent from the Israel Patent Office for its Reqorsa® gene therapy combined with PD-1 antibodies for cancer treatment. This patent adds to the existing global patent portfolio and reinforces the company's position in the cancer therapy market. The company aims to improve treatment outcomes for lung cancer patients through this innovative approach.
Read more →GNPXGenprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
Genprex, Inc. announced that its collaborators will present positive preclinical data on their diabetes gene therapy at the 2026 ASGCT Annual Meeting. The therapy, which utilizes Pdx1/MafA gene therapy, demonstrated the ability to reverse hyperglycemia in Type 2 diabetic mouse models within four weeks. This advancement suggests a promising new treatment paradigm for managing Type 2 diabetes.
Read more →GNPX▼ -6.4%on this news
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting
Genprex, Inc. announced that its abstract on positive clinical data regarding predictive biomarkers in lung cancer patients receiving Reqorsa® Gene Therapy has been selected for the 2026 ASCO Annual Meeting. The research may enhance the understanding of patient responses to treatment, potentially leading to better outcomes. The meeting will take place from May 29 to June 2, 2026, in Chicago.
Read more →GNPX▼ -5.6%on this newsshared move
Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy
Genprex, Inc. announced a Sponsored Research Agreement with the University of Texas MD Anderson Cancer Center to study biomarkers that may predict responses to its Reqorsa gene therapy for lung cancer patients. This partnership aims to enhance patient selection strategies for ongoing clinical trials, Acclaim-1 and Acclaim-3, which are evaluating the efficacy of Reqorsa in combination with other therapies. Preclinical studies have identified biomarkers TROP2 and PTEN, which could improve treatment outcomes by predicting which patients may benefit most from the therapy. Overall, this initiative highlights Genprex's commitment to tailored treatments for cancer patients.
Read more →GNPX▼ -11.2%on this news· ran to -22% by day 3shared move
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
Genprex, Inc. announced positive preclinical data for its Reqorsa® Gene Therapy at the 2026 AACR Annual Meeting. The therapy demonstrated the ability to induce apoptosis and reduce tumor volume in non-small cell lung cancer (NSCLC) models, including those resistant to existing treatments. Biomarkers TROP2 and PTEN were identified as potential indicators for patient response, enhancing precision medicine strategies. The findings support Reqorsa's potential as both a standalone treatment and an adjunct therapy.
Read more →GNPXGenprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
Genprex, Inc. announced that their research collaborators will present promising preclinical data for their lead gene therapy candidate, Reqorsa, at the 2026 AACR Annual Meeting. The data highlights Reqorsa's potential in treating non-small cell lung cancer, particularly for patients resistant to existing therapies. Important biomarkers, TROP2 and PTEN, have been identified that may predict patient response, which could refine patient selection and enhance therapy effectiveness. The studies suggest strong pro-apoptotic effects and improved tumor responses when combining Reqorsa with existing therapies such as alectinib.
Read more →GNPXGenprex to Participate at BIO Europe Spring 2026
Genprex, Inc. announced its participation at BIO Europe Spring from March 23-25, 2026, in Lisbon, Portugal. Key executives, including CEO Ryan Confer, will conduct meetings to discuss the company’s gene therapies aimed at treating cancer and diabetes. The event is anticipated to attract over 3,700 leaders from the biotech and pharmaceutical sectors, facilitating significant networking opportunities. Genprex is focused on advancing innovative treatment options through its clinical-stage gene therapy research.
Read more →GNPX▲ +27.5%on this news
Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer
Genprex has received patents from the Japanese and European Patent Offices for its Reqorsa gene therapy in combination with immunotherapies to treat cancer. This strengthens the company's intellectual property portfolio and supports its ongoing Acclaim-3 clinical trial for small cell lung cancer. The trial evaluates Reqorsa alongside Genentech's Tecentriq as maintenance therapy.
Read more →GNPXGenprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
Genprex, Inc. announced that IP Australia intends to grant a patent for its Reqorsa® Gene Therapy in combination with PD-L1 antibodies for cancer treatment. This patent, which has been granted in other countries, will enhance Genprex's intellectual property portfolio. Additionally, the company has opened a new clinical trial site for its Acclaim-3 trial, which evaluates this therapy in patients with extensive stage small cell lung cancer.
Read more →GNPXGenprex Provides Clinical Update on Diabetes Gene Therapy Program
Genprex, Inc. has announced significant advancements in its diabetes gene therapy program for GPX-002, focusing on Type 2 diabetes. The company has achieved key milestones, including successful preclinical research and a strategic partnership for production. They are preparing for regulatory submissions to advance to human clinical trials, marking a pivotal step in their development efforts.
Read more →GNPXGenprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies
Genprex, Inc. announced promising preliminary preclinical data for its diabetes gene therapy, GPX-002, which demonstrates the ability to rejuvenate beta cells in Type 2 diabetic non-human primates and mice. The therapy showed improvements in glucose tolerance and insulin production over study periods. With plans for further studies and eventual human clinical trials, the company believes GPX-002 may provide significant advancements in diabetes treatment. However, research is still in its early stages, and future clinical results remain uncertain.
Read more →GNPX▼ -6.7%on this news
Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer
Genprex, Inc. announced the publication of data from its Acclaim-1 Phase 1 clinical trial of Reqorsa gene therapy combined with Tagrisso for advanced non-small cell lung cancer. The trial showed promising efficacy with no reported Dose Limiting Toxicities and established a Recommended Phase 2 Dose. Patients experienced prolonged time to progression, indicating potential benefits of the treatment.
Read more →About Genprex, Inc.
Headquarters3300 BEE CAVE ROAD SUITE 650-227, AUSTIN, TX, 78746
BIOPHARMAWATCH ELITE PLUS
Trade the next GNPX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime